The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
 
Ellen K. Ritchie
Consulting or Advisory Role - bristol myers squibb; Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - Celgene; Incyte
Research Funding - Astellas Pharma (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Tara L. Lin
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Celyad (Inst); CicloMed (Inst); Cleave Biosciences (Inst); Jazz Pharmaceuticals (Inst)
 
Laura F. Newell
No Relationships to Disclose
 
Robert K. Stuart
No Relationships to Disclose
 
Scott R. Solomon
No Relationships to Disclose
 
Richard M. Stone
Honoraria - DAVA Pharmaceuticals; Medscape; Prime Oncology; Research to Practice
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Amgen; Aprea Therapeutics; Aptevo Therapeutics; Arog; AvenCell; BerGenBio; Boston Pharmaceuticals; Bristol Myers Squibb; CTI BioPharma Corp; ElevateBio; Epizyme; Foghorn Therapeutics; Gemoab; GlaxoSmithKline; Innate Pharma; Janssen; Jazz Pharmaceuticals; Kura Oncology; Novartis; Onconova Therapeutics; Rigel; Syndax; Syntrix Biosystems; Syros Pharmaceuticals; Takeda
Research Funding - Abbvie/Genentech (Inst); Agios (Inst); Novartis (Inst)
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; AVM Biotechnology; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Matthew Joseph Wieduwilt
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Gilead Sciences; SERVIER
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Gilead Sciences; Pfizer; SERVIER
Research Funding - NCI (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
Other Relationship - Sorrento Therapeutics
 
Eileen A. Ryan
No Relationships to Disclose
 
Nalina Dronamraju
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Jeffrey E. Lancet
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Abbvie; BerGenBio; Boxer Capital; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; ElevateBio; Jazz Pharmaceuticals; Medtalks; Millennium; Novartis; RW Baird; Servier/Pfizer; The Dedham Group
 
Jorge E. Cortes
Consulting or Advisory Role - Bio-Path Holdings, Inc; Bristol-Myers Squibb; Centessa Pharmaceuticals; Gilead Sciences; Menarini; Novartis; Pfizer; Takeda
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst); Takeda (Inst)